Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-07-07T17:41:47.806Z Has data issue: false hasContentIssue false

83 - Anti-estrogens and selective estrogen-receptor modulators

from Part 4 - Pharmacologic targeting of oncogenic pathways

Published online by Cambridge University Press:  05 February 2015

Ping Fan
Affiliation:
Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University, DC, USA
V. Craig Jordan
Affiliation:
Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University, DC, USA
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Introduction, definitions and scope

The estrogen receptor (ER), including estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), mediates the biological effects of estrogen for the development and progression of breast cancer, and it serves as an important diagnostic and therapeutic target for prevention and treatment of breast cancer. Targeted estrogen-receptor therapy is the most successful strategy in breast cancer treatment and prevention. These endocrine therapies include aromatase inhibitors (AIs) indirectly targeting the ER that block the synthesis of estrogen from androgen in peripheral tissues and show efficacy in post-menopausal breast cancer patients. Another direct strategy is to use pure anti-estrogens (also called selective estrogen-receptor down-regulators, SERDs), such as fulvestrant, which have no agonist activity and cause degradation of the ER. Fulvestrant has been approved to treat advanced breast cancer after tamoxifen failure. The most widely used therapy for ER-positive breast cancer is selective estrogen receptor modulators (SERMs), which are synthetic molecules that bind to the ER and can modulate its transcriptional capabilities in different ways in diverse estrogen target tissues. Tamoxifen, the pioneering SERM, is extensively used for targeted therapy of ER-positive breast cancers, and is also approved as the first chemo-preventive agent for lowering breast cancer incidence in high-risk women. The therapeutic and preventive efficacy of tamoxifen was initially proven by a series of experiments in the laboratory that laid the foundation for its clinical use. Unfortunately, use of tamoxifen is associated with de novo and acquired resistance, and some undesirable side effects. The molecular study of resistance provides an opportunity to precisely understand the mechanism of action of SERMs, which may further help in designing new and improved SERMs. Clinical studies demonstrate that another SERM, raloxifene, which is primarily used to treat post-menopausal osteoporosis, is as effective as tamoxifen in preventing breast cancer in post-menopausal women, but with fewer side effects. Overall, these findings open a new horizon for SERMs as a class of drug which can not only be used for therapy and prevention of breast cancer, but also for various other diseases and disorders. We will provide a basic background of anti-estrogens, the current utility of the two pioneering SERMs tamoxifen and raloxifene, discuss in detail the putative mechanism of action of SERMs, and consider progress with new SERMs.

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 884 - 892
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jordan, VC. Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. Journal of Steroid Biochemistry 1974;5:354.CrossRefGoogle Scholar
Jordan, VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA- induced rat mammary carcinoma. European Journal of Cancer 1976;12:419–24.CrossRefGoogle Scholar
Schwarzel, WC, Kruggel, WG, Brodie, HJ. Studies on the mechanism of estrogen biosynthesis: the development of inhibitors of the enzyme system in human placenta. Endocrinology 1973;92:866–80.CrossRefGoogle ScholarPubMed
Brodie, AM, Schwarzel, WC, Shaikh, AA, Brodie, HJ. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 1977;100:1684–95.CrossRefGoogle ScholarPubMed
Coombes, CR, Goss, P, Dowsett, M, Gazet, JC, Brodie, A. 4-Hydroxy andostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984;1:1237–9.CrossRefGoogle Scholar
Goss, P, Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer. Journal of Clinical Oncology 2001;19:881–94.CrossRefGoogle ScholarPubMed
Thurlimann, B, Keshaviah, A, Coates, AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 2005;353:2747–57.Google ScholarPubMed
Howell, A, Cuzick, J, Baum, M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2.Google ScholarPubMed
Goss, PE, Ingle, JN, Martino, S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. Journal of the National Cancer Institute 2005;97:1262–71.CrossRefGoogle ScholarPubMed
Bonneterre, J, Thurlimann, B, Robertson, JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. Journal of Clinical Oncology 2000;18:3748–57.CrossRefGoogle ScholarPubMed
Coombes, RC, Hall, E, Gibson, LJ, et al. The Intergroup Exemestane Study, a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 2004;350:1081–92.CrossRefGoogle ScholarPubMed
Jordan, VC, Brodie, AMH. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7–25.CrossRefGoogle ScholarPubMed
Perez, EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Annals of Oncology 2007;18:viii26–35.CrossRefGoogle ScholarPubMed
Dauvois, S, Danielian, PS, White, R, Parker, MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences USA 1992;89:4037–41.CrossRefGoogle ScholarPubMed
Gibson, MK, Nemmers, LA, Beckman, WC, et al. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991;129:2000–10.CrossRefGoogle ScholarPubMed
DeFriend, DJ, Howell, A, Nicholson, RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research 1994;54:408–14.Google ScholarPubMed
Chia, S, Gradishar, W, Mauriac, L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. Journal of Clinical Oncology 2008;26:1664–70.CrossRefGoogle ScholarPubMed
Jordan, VC. Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2003;2:205–13.CrossRefGoogle ScholarPubMed
Veronesi, U, Boyle, P, Goldhirsch, A, Orecchia, R, Viale, G. Breast cancer. Lancet 2005;365:1727–41.CrossRefGoogle ScholarPubMed
Strasser-Weippl, K, Goss, PE. Advances in adjuvant hormonal therapy for postmenopausal women. Journal of Clinical Oncology 2005;23:1751–9.CrossRefGoogle ScholarPubMed
Cuzick, J, Baum, M. Tamoxifen and contralateral breast cancer [letter]. Lancet 1985;2:282.CrossRefGoogle Scholar
Jordan, VC. Tamoxifen: catalyst for the change to targeted therapy. European Journal of Cancer 2008;44:30–8.CrossRefGoogle ScholarPubMed
Fisher, B, Dignam, J, Bryant, J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 1996;88:1529–42.CrossRefGoogle ScholarPubMed
Fisher, B, Dignam, J, Bryant, J, Wolmark, N. Five versus more than five years of tamoxifen for lymph node negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. Journal of the National Cancer Institute 2001;93:684–90.CrossRefGoogle ScholarPubMed
Jordan, VC, Gapstur, S, Morrow, M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute 2001;93:1449–57.CrossRefGoogle ScholarPubMed
Powles, TJ, Ashley, S, Tidy, A, Smith, IE, Dowsett, M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute 2007;99:283–90.CrossRefGoogle Scholar
Fisher, B, Costantino, JP, Wickerham, DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998;90:1371–88.CrossRefGoogle ScholarPubMed
Fisher, B, Costantino, JP, Wickerham, DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 2005;97:1636–7.CrossRefGoogle ScholarPubMed
Cuzick, J, Powles, T, Veronesi, U, et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003;361:296–300.CrossRefGoogle ScholarPubMed
Jordan, VC. The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute 2008 18;100:831–3.CrossRefGoogle Scholar
Morrow, M, Jordan, VC. The current status of breast cancer chemoprevention: a star is born. Journal of Surgical Oncology 2007;95:4–5.CrossRefGoogle ScholarPubMed
Cummings, SR, Eckert, S, Krueger, KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial, Multiple Outcomes of Raloxifene Evaluation. Journal of the American Medical Association 1999;281:2189–97.CrossRefGoogle ScholarPubMed
Ettinger, B, Black, DM, Mitlak, BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments]. Journal of the American Medical Association 1999;282:637–45. Erratum in: Journal of the American Medical Association 1999;282:2124.CrossRefGoogle Scholar
Vogel, VG, Costantino, JP, Wickerham, DL, et al. The Study of Tamoxifen and Raloxifene (STAR): report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. Journal of the American Medical Association 2006;295:2727–41. Erratum in: Journal of the American Medical Association 2006;296:2926. Journal of the American Medical Association 2007;298:973.CrossRefGoogle Scholar
DeMichele, A, Troxel, AB, Berlin, JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. Journal of Clinical Oncology 2008;26:4151–9.CrossRefGoogle ScholarPubMed
Martino, S, Cauley, JA, Barrett-Connor, E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute 2004; 96:1751–61.CrossRefGoogle Scholar
Jordan, VC. Tamoxifen (ICI 46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology 2006;147:S269–76.CrossRefGoogle ScholarPubMed
Osborne, CK. Tamoxifen in the treatment of breast cancer. New England Journal of Medicine 1998;339:1609–18.CrossRefGoogle ScholarPubMed
Lerner, LJ, Jordan, VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Research 1990;50:4177–89.Google ScholarPubMed
Jordan, VC. SERMs: meeting the promise of multifunctional medicines. Journal of the National Cancer Institute 2007;99:350–6.CrossRefGoogle ScholarPubMed
Shang, Y, Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465–8.CrossRefGoogle ScholarPubMed
O’Regan, RM, Cisneros, A, England, GM, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. Journal of the National Cancer Institute 1998;90:1552–8.CrossRefGoogle ScholarPubMed
Grese, TA, Sluka, JP, Bryant, HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proceedings of the National Academy of Sciences USA 1997;94:14 105–10.CrossRefGoogle ScholarPubMed
Fornander, T, Rutqvist, LE, Cedermark, B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117–20.CrossRefGoogle ScholarPubMed
Gottardis, MM, Robinson, SP, Satyaswaroop, PG, Jordan, VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 1988;48: 812–15.Google ScholarPubMed
Gottardis, MM, Ricchio, ME, Satyaswaroop, PG, Jordan, VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Research 1990;50:3189–92.Google Scholar
O’Malley, BW, Kumar, R. Nuclear receptor coregulators in cancer biology. Cancer Research 2009;69:8217–22.CrossRefGoogle ScholarPubMed
O’Malley, BW. Little molecules with big goals. Science 2006;313:1749–50.CrossRefGoogle ScholarPubMed
Onate, SA, Tsai, SY, Tsai, MJ, O’Malley, BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354–7.Google ScholarPubMed
Smith, CL, O’Malley, BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 2004;25:45–71.CrossRefGoogle ScholarPubMed
Shang, Y, Hu, X, DiRenzo, J, Lazar, MA, Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103:843–52.CrossRefGoogle ScholarPubMed
Shiau, AK, Barstad, D, Loria, PM, et al. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927–37.CrossRefGoogle Scholar
Brzozowski, AM, Pike, AC, Dauter, Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753–8.CrossRefGoogle ScholarPubMed
Wijayaratne, AL, Nagel, SC, Paige, LA, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999;140:5828–40.CrossRefGoogle ScholarPubMed
Xu, J, Wu, RC, O’Malley, BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature Reviews Cancer 2009;9:615–30.CrossRefGoogle ScholarPubMed
Jordan, VC, O’Malley, BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Journal of Clinical Oncology 2007;25:5815–24.CrossRefGoogle ScholarPubMed
Jordan, VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007;72:829–42.CrossRefGoogle Scholar
Jin, Y, Desta, Z, Stearns, V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute 2005;97:30–9.CrossRefGoogle ScholarPubMed
Weinshilboum, R. Pharmacogenomics of endocrine therapy in breast cancer. Advances in Experimental Medicine and Biology 2008;630:220–31.CrossRefGoogle ScholarPubMed
Brauch, H, Jordan, VC. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the “personalised” approach?European Journal of Cancer 2009;45:2274–83.CrossRefGoogle ScholarPubMed
Stearns, V, Johnson, MD, Rae, JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 2003;95:1758–64.CrossRefGoogle ScholarPubMed
Schroth, W, Goetz, MP, Hamann, U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Journal of the American Medical Association 2009;302:1429–36.CrossRefGoogle ScholarPubMed
Flockhart, D.CYP2D6 genotyping and the pharmacogenetics of tamoxifen. Clinical Advances in Hematology and Oncology 2008;6:493–4.Google ScholarPubMed
Borges, S, Desta, Z, Li, L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clinical Pharmacology and Therapeutics 2006;80:61–74.CrossRefGoogle ScholarPubMed
Harvell, DM, Richer, JK, Singh, M, et al. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Research and Treatment 2008;112:489–501.CrossRefGoogle ScholarPubMed
Bloom, ND, Tobin, EH, Schreibman, B, Degenshein, GA. The role of progesterone receptor in the management of advanced breast cancer. Cancer 1980;45:2992–7.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
Osborne, CK, Yochmowitz, MG, Knight, WA 3rd, McGuire, WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884–8.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
Cormier, EM, Wolf, MF, Jordan, VC. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Research 1989;49:576–80.Google ScholarPubMed
Cormier, EM, Jordan, VC. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. European Journal of Cancer and Clinical Oncology 1989;25:57–63.CrossRefGoogle ScholarPubMed
Robinson, SP, Jordan, VC. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. European Journal of Cancer and Clinical Oncology 1989:25:493–7.CrossRefGoogle ScholarPubMed
Cui, X, Zhang, P, Deng, W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: Progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular Endocrinology 2003;17:575–88.CrossRefGoogle ScholarPubMed
Arpino, G, Weiss, H, Lee, AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. Journal of the National Cancer Institute 2005;97:1254–61.CrossRefGoogle ScholarPubMed
Benz, CC, Scott, GK, Sarup, JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 1992;24:85–95.CrossRefGoogle ScholarPubMed
Gottardis, MM, Jordan, VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 1988;48:5183–7.Google ScholarPubMed
Kato, S, Endoh, H, Masuhiro, Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491–4.CrossRefGoogle ScholarPubMed
Bunone, G, Briand, PA, Miksicek, RJ, Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 1996;15:2174–83.Google ScholarPubMed
Pietras, RJ, Arboleda, J, Reese, DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435–46.Google ScholarPubMed
Osborne, CK, Bardou, V, Hopp, TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC3) and HER2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 2003;95:353–61.CrossRefGoogle Scholar
Shou, J, Massarweh, S, Osborne, CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 2004;96:926–35.CrossRefGoogle ScholarPubMed
Smith, CL, Nawaz, Z, O‘Malley, BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 1997;11:657–66.CrossRefGoogle ScholarPubMed
Takimoto, GS, Graham, JD, Jackson, TA, et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. Journal of Steroid Biochemistry and Molecular Biology 1999;69:45–50.CrossRefGoogle ScholarPubMed
Girault, I, Lerebours, F, Amarir, S, et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clinical Cancer Research 2003;9:1259–66.Google ScholarPubMed
Osborne, CK, Pippen, J, Jones, SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 2002;20:3386–95.CrossRefGoogle ScholarPubMed
Howell, A, Robertson, JF, Quaresma Albano, J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 2002;20:3396–403.CrossRefGoogle ScholarPubMed
Johnston, SR, Saccani-Jotti, G, Smith, IE, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 1995;55:3331–8.Google ScholarPubMed
Gutierrez, MC, Detre, S, Johnston, S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 2005;23:2469–76.CrossRefGoogle ScholarPubMed
Normanno, N, Di Maio, M, De Maio, E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-Related Cancer 2005;12:721–47.CrossRefGoogle ScholarPubMed
Fan, P, Wang, J, Santen, RJ, Yue, W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Research 2007;67:1352–60.CrossRefGoogle ScholarPubMed
Nicholson, RI, Gee, JMW. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. British Journal of Cancer 2000;82:501–13.CrossRefGoogle ScholarPubMed
Long, B, McKibben, BM, Lynch, M, van den Berg, HW. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75–1 human breast cancer cell line. British Journal of Cancer 1992;65:865–9.CrossRefGoogle ScholarPubMed
Massarweh, S, Osborne, CK, Creighton, CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research 2008;68:826–33.CrossRefGoogle ScholarPubMed
Hiscox, S, Morgan, L, Green, TP, et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Research and Treatment 2006; 97:263–74.CrossRefGoogle ScholarPubMed
Zhao, Y, Planas-Silva, MD. Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity. Cancer Letters 2009;275:204–12.CrossRefGoogle ScholarPubMed
Jordan, VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207–13.CrossRefGoogle Scholar
Yao, K, Lee, ES, Bentrem, DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research 2000;6:2028–36.Google ScholarPubMed
Jordan, VC. The 38th David A. Karnofsky Lecture. The paradoxical actions of estrogen in breast cancer: survival or death? Journal of Clinical Oncology 2008;26:3073–82.CrossRefGoogle ScholarPubMed
Jordan, VC, Lewis, JS, Osipo, C, Cheng, D. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast 2005;14:624–30.CrossRefGoogle ScholarPubMed
Lønning, PE, Taylor, PD, Anker, G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment 2001;67:111–16.CrossRefGoogle ScholarPubMed
Ellis, MJ, Gao, F, Dehdashti, F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. Journal of the American Medical Association 2009;302:774–80.CrossRefGoogle ScholarPubMed
Nicholson, RI, Hutcheson, IR, Hiscox, SE, et al. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 2005;12:S29–36.CrossRefGoogle ScholarPubMed
Hiscox, S, Jordan, NJ, Smith, C, et al. Dual targeting of SRC and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 2009;115:57–67.CrossRefGoogle ScholarPubMed
Peng, J, Sengupta, S, Jordan, VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents in Medicinal Chemistry 2009;9:481–99.CrossRefGoogle ScholarPubMed
Ariazi, EA, Jordan, VC. Estrogen receptors as therapeutic targets in breast cancer. In: Ottow E, Weinmann H, editors. Nuclear receptors as drug targets. Weinheim: Wiley-VCH;2008:127–99.CrossRefGoogle Scholar
Jordan, VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. Journal of Medicinal Chemistry 2003;46:1081–111.CrossRefGoogle ScholarPubMed
Cummings, SR, Ensrud, K, Delmas, PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. New England Journal of Medicine 2010;362:686–96.CrossRefGoogle ScholarPubMed
Jordan, VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Research 2009;69:1243–54.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×